Systems biology approach to precision oncology using SYGNAL

FastSmartPrecise Blueprints for Cures

The SYGNAL (Systems Genetics Network Analysis) intelligence platform is based on systems biology and machine learning and generates predictive, actionable, patient-specific blueprints.

Our proven approach identifies high-risk cancer subtypes and will help you discover new targets, drugs, and drug combinations specifically matched to patients.

We are currently seeking clinical partnerships in the treatment of Multiple Myeloma and Glioblastoma.

Learn More

TEAM

Nitin S Baliga

Founder and Board Member

Science

Ashutosh Tiwary

Founder and Board Member

Technology & Business

Ed Truitt

Founding Team Member

Business Advisor

Thomas Brown

Founding Team Member

Clinical Advisor

Anoop Patel M.D.

Founding Team Member

Clinical

Serdar Turkarslan

Founding Team Member

Science

PUBLICATIONS

  • Genetic program activity delineates risk, relapse, and therapy responsiveness in Multiple Myeloma

    Matthew A. Wall, Serdar Turkarslan, Wei-Ju Wu, Samuel A. Danziger, David J. Reiss, Mike J. Mason, Andrew P. Dervan, Matthew W.B. Trotter, Douglas Bassett, Robert M. Hershberg, Adrián López García de Lomana, Alexander V. Ratushny, Nitin S. Baliga
    doi: https://doi.org/10.1101/2020.04.01.0123 Nature Precision Oncology (in press)

  • Causal Mechanistic Regulatory Network for Glioblastoma Deciphered Using Systems Genetics Network Analysis

    Christopher L. Plaisier, Sofie O’Brien, Brady Bernard, Sheila Reynolds, Zac Simon, Chad M. Toledo, Yu Ding, David J. Reiss, Patrick J. Paddison, and Nitin S. Baliga
    doi: https://doi.org/10.1016/j.cels.2016.06.006 Cell Systems, VOLUME 3, ISSUE 2, P172-186, AUGUST 24, 2016

  • A single-cell based precision medicine approach using glioblastoma patient-specific models.

    James H. Park, Abdullah H. Feroze, Samuel N. Emerson, Anca B. Mihalas, C. Dirk Keene, Patrick J. Cimino, Adrian Lopez Garcia de Lomana, Kavya Kannan, Wei-Ju Wu, Serdar Turkarslan, Nitin S. Baliga, Anoop P. Patel., doi: https://doi.org/10.1101/2021.01.13.426485 bioRxiv, 2021.2001.2013.426485 (2021) & Nature Precision Oncology (in review)

  • Harnessing the power of human tumor-derived cell lines for the rational design of cancer therapies.

    Plaisier, C.L. & Baliga, N.S., doi: https://doi.org/10.1111/j.1755-148x.2012.01020.x Pigment Cell Melanoma Res 25 (4), 406-408 (2012).

    ,

  • miRvestigator: web application to identify miRNAs responsible for co-regulated gene expression patterns discovered through transcriptome profiling.

    Plaisier, C.L., Bare, J.C., & Baliga, N.S., doi: https://doi.org/10.1093/nar/gkr374 Nucleic Acids Res. 39 (Web Server issue), W125-131 (2011).

    ,

  • A miRNA-regulatory network explains how dysregulated miRNAs perturb oncogenic processes across diverse cancers.

    Plaisier, C.L., Pan, M., & Baliga, N.S., doi: https://dx.doi.org/10.1101%2Fgr.133991.111 Genome Res. 22 (11), 2302-2314 (2012).

    ,

This study is a collaboration with Institute for Systems Biology (ISB), a non-profit biomedical research organization and affiliate of Providence.

CONTACT US